
Loading, please wait...

Loading, please wait...

Dry eye disease presents an escalating challenge for eye care specialists worldwide. Clinicians often face significant hurdles when prescribing topical therapeutics because tear turnover and nasolacrimal drainage rapidly eliminate instilled drops. Rebamipide acts as a mucosal secretagogue that boosts mucin production and stabilizes tear dynamics. However, poor aqueous solubility and limited corneal permeability significantly restrict the clinical utility of rebamipide in dry eye management. Consequently, nanotechnology offers an innovative pathway to conquer these formidable ocular barriers.
Dry eye disease represents a multifactorial ocular disorder characterized by tear film instability, hyperosmolarity, and ocular surface inflammation. Within this pathological cascade, mucin deficiency plays a pivotal role in accelerating tear film breakup. Rebamipide, an amino acid derivative of 2-(1H)-quinolinone, directly stimulates the endogenous expression of membrane-associated mucins like MUC1, MUC4, and MUC16 on corneal epithelial cells. Furthermore, the molecule promotes conjunctival goblet cell differentiation, thereby increasing secreted MUC5AC production. In addition to mucin restoration, rebamipide exhibits potent anti-inflammatory properties by suppressing reactive oxygen species and cytokine release.
Nevertheless, commercial ophthalmic suspensions demonstrate critical physiological limitations. Specifically, the drug displays exceptionally poor aqueous solubility and hydrophobic characteristics. Consequently, traditional eye drops require frequent daily instillations, typically four times daily, to maintain therapeutic concentrations. Patients frequently complain of transient blurred vision and unpleasant foreign body sensations due to coarse suspended particles. Moreover, rapid nasolacrimal drainage clears the majority of the instilled dose within minutes. Therefore, ophthalmic researchers actively develop advanced delivery platforms to enhance ocular residence time and corneal absorption.
To address these pharmacokinetic obstacles, pharmaceutical scientists fabricated a specialized nanocarrier platform designated as LeciPlex. Specifically, the fabrication process leveraged a single-step nanoprecipitation technique governed by a robust 2³ full factorial design. The formulated nanoplatform successfully combines soybean lecithin, a cationic surfactant, and a biocompatible chitosan biopolymer coat. Phospholipids provide structural biocompatibility and membrane-mimetic affinity, whereas chitosan confers superior mucoadhesive functionality.
The optimized nanovesicles exhibited a mean hydrodynamic diameter of 165 ± 1.55 nanometers with a polydispersity index of 0.53 ± 0.04. This nanoscale dimension ensures smooth corneal distribution without triggering ocular irritation or visual distortion. Additionally, the nanocarriers demonstrated an exceptional drug entrapment efficiency of 97.75 ± 0.06%. This high loading capacity ensures that substantial rebamipide reserves remain encapsulated within the core matrix. Furthermore, transmission electron microscopy verified the formation of uniform, spherical vesicular architectures. Crucially, the formulation exhibited a physiological pH profile, ensuring complete compatibility with delicate human ocular tissues. Consequently, the nanocarriers establish a robust formulation baseline for targeted ocular delivery.
Corneal epithelial surfaces and the preocular tear film maintain a net negative electrostatic charge due to sialic acid residues within mucin glycocalyx layers. Consequently, conventional uncharged or negatively charged formulations face immediate clearance during normal blinking cycles. In contrast, the engineered chitosan-coated LeciPlex formulation achieved a prominent positive zeta potential of 49.7 ± 1.97 millivolts. This positive electrostatic charge establishes strong ionic interactions with anionic mucosal surfaces.
Therefore, the cationic nanocarriers adhere intimately to the corneal and conjunctival epithelium, markedly delaying nasolacrimal elimination. In vitro dissolution assays revealed sustained drug release kinetics, releasing 74.02 ± 3.85% of entrapped rebamipide continuously over a 24-hour timeframe. Moreover, rheological characterization confirmed favorable shear-thinning behavior. Under resting conditions between blinks, the formulation exhibits higher viscosity to preserve ocular residence time. In addition, when the eyelid blinks, ocular shear stress instantaneously lowers viscosity, thereby preventing ocular discomfort and visual obstruction. Hence, this dual electro-rheological mechanism provides optimal drug retention on the anterior ocular surface.
Overcoming the corneal epithelial barrier remains one of the greatest challenges in anterior segment drug development. The cornea features tight junctions between superficial epithelial cells, which restrict paracellular transport of hydrophobic compounds. However, the chitosan coating temporarily and reversibly modulates these epithelial tight junctions. Consequently, in vitro and ex vivo tissue studies demonstrated a remarkable 2.1-fold enhancement in corneal drug permeation compared to standard drug suspensions.
In addition to permeability, ocular biocompatibility represents an essential prerequisite for any translational ophthalmic platform. Preclinical safety evaluations using standardized Draize ocular irritation tests confirmed excellent ocular tolerability. Specifically, rabbits treated with the optimized nanocarrier formulation exhibited zero conjunctival redness, corneal opacity, or chemosis. Histological assessments similarly revealed intact corneal architecture without cellular necrosis or inflammatory infiltration. Thus, the cationic lipid-polymer hybrid system effectively reconciles enhanced drug penetration with outstanding local safety. These findings confirm that nanocarrier encapsulation eliminates the mechanical irritation commonly caused by traditional microcrystalline rebamipide eye drops.
The therapeutic potential of this advanced nanocarrier translated into significant in vivo clinical benefits in dry eye animal models. Specifically, animals receiving the chitosan-coated LeciPlex formulation demonstrated an impressive 2.36-fold increase in tear production volume compared to baseline control cohorts. This pronounced elevation in tear secretion reflects both sustained local drug bioavailability and accelerated goblet cell recovery. Furthermore, by providing continuous mucin stimulation over 24 hours, the formulation restores preocular tear stability and reverses epithelial desiccation.
From a clinical perspective, these pharmacokinetic enhancements could revolutionize patient adherence. Standard rebamipide regimens demand four instillations per day, leading to poor compliance and disease relapse. Conversely, a sustained-release nanocarrier system could potentially support once-daily or twice-daily dosing schedules. Furthermore, preventing ocular blur and bitter post-nasal drainage will likely enhance treatment satisfaction among dry eye sufferers. As clinical development progresses, this nanomedicine approach offers great promise for patients suffering from severe aqueous-deficient and evaporative dry eye syndromes. Therefore, ophthalmic clinicians may soon gain a potent therapeutic alternative for refractory ocular surface disease.
Rebamipide functions as a dedicated mucosal secretagogue that directly upregulates mucin production on the ocular surface. It stimulates the genetic expression of membrane-spanning mucins, including MUC1, MUC4, and MUC16, within corneal epithelial cells. Additionally, it increases conjunctival goblet cell density, elevating secreted gel-forming MUC5AC. These integrated actions restore the hydrophobic-hydrophilic barrier between tears and ocular cells, markedly reducing tear breakup time and protecting epithelial tissues against desiccating environmental stress.
Chitosan is a natural cationic biopolymer that provides indispensable mucoadhesive properties to the lipid nanocarrier core. Because the preocular mucin layer carries a strong negative electrostatic charge, chitosan-coated particles generate powerful ionic attractions that resist nasolacrimal drainage. Furthermore, chitosan temporarily relaxes epithelial tight junctions, facilitating enhanced drug permeation across the corneal barrier. Consequently, the coating dramatically extends formulation residence time, preventing premature drug clearance and eliminating the need for frequent daily drop administration.
Conventional rebamipide suspensions suffer from poor aqueous solubility, rapid ocular drainage, and unpleasant visual blurring from particulate matter. In contrast, the chitosan-coated LeciPlex system encapsulates rebamipide into sub-200-nanometer vesicles, ensuring optical transparency and comfortable administration. The platform achieved a 2.1-fold increase in tissue permeation, a 2.36-fold improvement in tear volume, and sustained drug release over 24 hours. These significant enhancements reduce required dosing frequency while maximizing therapeutic outcomes and patient compliance.
Disclaimer: This content is for informational and educational purposes only... Refer to the latest local and national guidelines for clinical practice.
References
Salama M et al. Rational Design of Chitosan-coated LeciPlex® Nanocarriers for Enhanced Ocular Delivery of Rebamipide in Dry Eye Disease. J Drug Target. 2026 Nov 21. doi: 10.1080/1061186X.2026.2767702. PMID: 43067600.
Eom Y, Chung SH, Chung TY, et al. Efficacy and safety of 1% and 2% rebamipide clear solution in dry eye disease: a multicenter randomized trial. BMC Ophthalmol. 2023;23(1):343.
Kinoshita S, Oshiden K, Awamura S, et al. A randomized, multicenter phase 3 study comparing 2% rebamipide ophthalmic suspension with 0.1% sodium hyaluronate ophthalmic solution in the treatment of dry eye. Ophthalmology. 2013;120(6):1158-1165.

Read summarized clinical updates, watch expert medical content, and earn CME certifications right from your smartphone.


A breakthrough study designs chitosan-coated LeciPlex nanocarriers to overcome solubility and permeability barriers of rebamipide in dry eye disease. The mucoadhesive nanoplatform demonstrates prolonged corneal retention, a 2.1-fold permeation increase, and a 2.36-fold tear volume gain without ocular toxicity.
Today

Drug safety management evolves across a therapeutic product's entire lifecycle. This review examines regulatory standards, active surveillance, AI-supported pharmacovigilance, and pragmatic strategies to mitigate clinical risk from bench to bedside.
Today

A landmark study reveals that congenital DLK1 deficiency in women with a history of central precocious puberty causes visceral adiposity, mitochondrial dysfunction, oxidative stress, and neutrophil activation, highlighting the critical need for lifelong cardiometabolic surveillance.
Today

Explore revascularisation strategies in dialysis-dependent chronic limb-threatening ischaemia. This review examines surgical bypass vs endovascular therapy, BEST-CLI trial findings, procedural morbidity, conduit availability, and multidisciplinary decision-making for optimal limb salvage.
Today

A recent cross-sectional analysis reveals that over a quarter of randomized controlled trials for non-specific low back pain face discontinuation or unknown status, while more than 36% of completed trials remain unpublished, exposing notable reporting gaps in spine and musculoskeletal clinical research.
Today

This case report examines the longitudinal CBCT evolution of Stage 2 MRONJ in a 70-year-old woman on denosumab at the site of a pre-existing mandibular dense bone island. It emphasizes the radiographic features, differential diagnosis, and multidisciplinary strategies required for high-risk bone lesions.
Today